Congratulations to Dr. Juliane Walz of the University of Tübingen who was recently honored at überDACHt – Roche Science & Innovation Summit with the “Best Overall Award” for the upcoming fibrolamellar clinical trial, FusionVac_22_02. The event in Basel, Switzerland on March 21, 2025, brought together researchers from Germany, Austria and Switzerland to discuss innovations in medical research.

The FusionVac_22_02 clinical trial, funded by FCF late last year, is planning to test the safety and efficacy of a peptide vaccine (Fusion-VAC-XS15) as a treatment for FLC patients who, after surgery or other treatment, are free of cancer as judged by radiological scans. The vaccine will be given alone, without additional immunotherapy or any other systemic agent, with the goal of significantly delaying or entirely preventing the return of the cancer.

The proposed trial has recently passed required regulatory and ethics committee reviews. Patient enrollment in the trial is expected to open in May 2025.

Notes: Photo courtesy of Roche. Pictured left to right – Katharina Gasser, General Manager of Roche Pharma Switzerland, Juliane Walz, University of Tübingen, Doris Schwindt, Head of Pharma Operations at Roche Pharma Ltd, and Alexander Muelhaupt, General Manager at Roche New Zealand.